PHASE-I STUDY ON BRUCEANTIN ADMINISTERED ON A WEEKLY SCHEDULE
- 1 January 1981
- journal article
- research article
- Vol. 65 (9-10) , 883-885
Abstract
Fifteen adult patients with advanced solid tumors received bruceantin at doses of 1.6-6.0 mg/m2 i.v. for 30 min/wk .times. 4, followed by a 2 wk rest. The dose-limiting toxic effect was nausea and vomiting, which was more severe in patients with hepatic metastases or liver function abnormalities. Other sporadic toxic effects included fever, chills, malaise, alopecia, hypotension, thrombocytosis and leukocytosis. Hematologic toxicity was insignificant. The recommended starting dose for phase II studies is 5 mg/m2 per wk .times. 4, every 6 wk, with a reduction to 3 mg/m2 for patients with hepatic metastases.This publication has 4 references indexed in Scilit:
- INITIAL CLINICAL-STUDIES WITH BRUCEANTIN1979
- PHASE-I TRIAL OF BRUCEANTIN1979
- Bruceantin, a novel inhibitor of peptide bond formationBiochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis, 1978
- MODE OF ACTION OF ANTITUMOR COMPOUND BRUCEANTIN, AN INHIBITOR OF PROTEIN-SYNTHESIS1976